| Literature DB >> 26453575 |
Roxanne Parslow1, Aarti Patel2, Lucy Beasant1, Kirstie Haywood3, Debbie Johnson1, Esther Crawley1.
Abstract
BACKGROUND: Paediatric chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME) is relatively common and disabling. Research is hampered because current patient-reported outcome measures (PROMs) do not capture outcomes that are important to children with CFS/ME. AIM: The aim of this study was to explore the aspects of life and health outcomes that matter to children with CFS/ME.Entities:
Keywords: Chronic Fatigue Syndrome; Myalgic Encephalomyelitis; Patient Reported Outcome; children; qualitative
Mesh:
Year: 2015 PMID: 26453575 PMCID: PMC4680202 DOI: 10.1136/archdischild-2015-308831
Source DB: PubMed Journal: Arch Dis Child ISSN: 0003-9888 Impact factor: 3.791
Comparison of characteristics of children at initial clinical assessment who were interviewed as part of the SMILE trial and PROMs study compared with children who were assessed and treated by the specialist service during the same period (2010–2012)
| SMILE trial | PROMs study | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study sample (n=13*) unless otherwise shown | CFS cohort (n=511) unless otherwise shown | p Value† | Study sample (n=13) unless otherwise shown | CFS cohort (n=530) unless otherwise shown | p Value† | |||||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | |||||||
| Age (years)‡ | 14.5 (1.5) | 14.0 (1.6) | 0.21 | 11.3 (2.7) | 13.7 (1.9) | <0.001 | ||||
| Female | 10 (76.9%) | 387 (75.7%) | 0.92 | 5 (38.5%) | 385 (72.6%) | 0.01 | ||||
| Time to assessment (months) | 12 | 12 (6–17) | 421 | 12 (8–24) | 0.40 | 9 | 8 (6–12) | 438 | 12 (8–24) | 0.07 |
| Chalder Fatigue score (0–33) | 13 | 26 (23–28) | 479 | 26 (22–29) | 0.78 | 13 | 24 (17–25) | 491 | 25 (22–28) | 0.07 |
| SF-36 physical function (0–100) | 13 | 50 (45–55) | 469 | 55 (35–70) | 0.96 | 11 | 50 (30–75) | 484 | 50 (30–70) | 0.85 |
| Anxiety (SCAS) (0–90) | 12 | 45 (21–58) | 449 | 30 (18–45) | 0.12 | 10 | 16 (8–26) | 465 | 29 (17–43) | 0.01 |
| No. of symptoms (0–14) | 13 | 9 (7–10) | 575 | 8 (7–10) | 0.52 | 13 | 8 (7–10) | 528 | 8 (6–10) | 0.91 |
| Anxiety (HADS) (0–21) | 13 | 12 (8–15) | 475 | 9 (6–12) | 0.09 | 8 | 7 (4–9) | 435 | 8 (5–12) | 0.23 |
| Depression (HADS) (0–21) | 12 | 9 (7–11) | 478 | 8 (5–10) | 0.10 | 8 | 7 (2–9) | 438 | 7 (2–9) | 0.31 |
| Visual analogue pain (0–100) | 12 | 42 (29–57) | 461 | 57 (24–73) | 0.28 | 12 | 61 (46–81) | 476 | 57 (24–73) | 0.24 |
| None | 0 (0.0%) | 101 (21.2%) | 0.24 | 4 (30.8%) | 104 (21.0%) | 0.57 | ||||
| 10% | 2 (15.4%) | 49 (10.3%) | 0 (0.0%) | 53 (10.7%) | ||||||
| 20% | 2 (15.4%) | 29 (6.1%) | 1 (7.7%) | 37 (7.5%) | ||||||
| 40% | 1 (7.7%) | 88 (18.5%) | 0 (0.0%) | 88 (17.7%) | ||||||
| 60% | 3 (23.1%) | 100 (21.0%) | 3 (23.1%) | 95 (19.2%) | ||||||
| 80% | 3 (23.1%) | 84 (17.6%) | 4 (30.7%) | 89 (17.9%) | ||||||
| 100% | 2 (15.4%) | 21 (4.4%) | 1 (7.7%) | 26 (5.4%) | ||||||
| Not applicable | 0 (0.0%) | 5 (1.1%) | 0 (0.0%) | 4 (0.8%) | ||||||
*Characteristics included for one child whose mother was interviewed (the child was not interviewed).
†χ2 tests for proportions, Kruskal–Wallis test for continuous measures.
‡Age for the SMILE study and the CFS cohort is age at first assessment. Age for the PROMs study is age at interview. This is because children were recruited from follow-up visits not at clinical assessment.
CFS, Chronic Fatigue Syndrome; HADS, Hospital Anxiety and Depression Scale; PROMs, patient-reported outcome measures; SCAS, Spence Children's Anxiety Scale; SMILE, Specialist Medical Intervention and Lightning Evaluation.
Figure 1A child's experience of living with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a conceptual model.